用于成人体重管理的新药获批,研究称患者治疗期内体重持续下降

新京报
Mar 07

3月6日,辉瑞中国宣布,国家药监局已批准其新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液(商品名为先维盈),用于在控制饮食和增加体力活动基础上对成人超重/肥胖患者的长期体重管理。该药也是目前唯一获批、完全由天然氨基酸组成的长效GLP-1药物,研究显示,患者在整个48周治疗期间体重持续下降,未出现平台期。  埃诺格鲁肽的创新机制源自2012年诺贝尔奖成果—G蛋白偶联受体(GPCR)的发现。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10